Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$6.71
−$0.20 · -2.89%
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Previous close
$6.71
−$0.20 · -2.89%
Regular session · ET · Market data may be delayed.
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Day range
Current $6.71
52-week range
Current $6.71
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
62
Undervalued
Sentiment
52
Mixed
Risk
53
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Day range
Current $6.71
52-week range
Current $6.71
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 40.52M USD | 37.75M USD | 36.68M USD | 41.42M USD | 36.89M USD |
| Cost of goods sold | 27.08M USD | 30.51M USD | 26.39M USD | 23.94M USD | 19.27M USD |
| Gross profit | 13.44M USD | 7.23M USD | 10.3M USD | 17.48M USD | 17.62M USD |
| Research and development | 2.2M USD | 2.76M USD | 5.57M USD | 7.74M USD | 4.31M USD |
| Selling, general, and administrative | 27.07M USD | 29.47M USD | 34.78M USD | 37.45M USD | 24.17M USD |
| Operating expenses | 30.42M USD | 33.38M USD | 45.86M USD | 67.14M USD | 29.63M USD |
| Interest income | — | — | — | 213K USD | — |
| Interest expense | 710K USD | 687K USD | 833K USD | — | 589K USD |
| Depreciation and amortization | 6.34M USD | 6.58M USD | 5.66M USD | 3.17M USD | 2.88M USD |
| Operating income | −16.98M USD | −26.15M USD | −35.56M USD | −49.66M USD | −12.01M USD |
| Net income | −17.26M USD | −26.75M USD | −36.78M USD | −47.47M USD | −9.8M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.50
11.77% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.39M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM2.08M0.00%77.55B USD0.19%$288.89+0.41%
iShares Russell 2000 Growth ETFIWO669.47K0.00%14.32B USD0.24%$367.63+0.54%
Vanguard Extended Market ETFVXF608.55K0.00%93.7B USD0.05%$237.76+0.68%
iShares Biotechnology ETFIBB570.48K0.01%10.3B USD0.44%$202.93+0.14%
iShares Russell 2000 Value ETFIWN550.86K0.00%14.28B USD0.24%$219.69+0.33%
Vanguard Russell 2000 ETFVTWO319.88K0.00%17.4B USD0.06%$116.76+0.36%
iShares Micro-Cap ETFIWC260.7K0.02%1.44B USD0.60%$190.84+0.39%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
